where experts go to learn about the FDA
FDA Law Blog where experts go to learn about FDA
Hyman, Phelps & McNamara, P.C.
Menu
Menu
  • Practices
  • Industries
  • FDA Regulatory Categories
  • Professionals
  • About Us
  • Contact
  • LinkedIn
  • Twitter
FDA Law Blog
News & Events
  • LinkedIn
  • Twitter
  • Recent Posts
    • The OTC Fee Fallout: Are Hundreds of Companies Ignoring FDA’s User Fee Requirements? July 3, 2025
    • HP&M Seeks Experienced Regulatory Expert July 2, 2025
    • Controlled Substance Reporting Isn’t Just for DEA Anymore July 1, 2025
    • The RFD Process: Time for Reform? June 30, 2025
    • New Report on Patent Litigation Settlements Says that they are Critically Necessary to Ensure Prompt Generic and Biosimilar Market Entry June 26, 2025
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Your search for “ 🌟 Order Stromectol 3mg Online Uk 🎗 www.Ivermectin-Stromectol.com 🎗 Stromectol 12mg Pills Uk 😉 Order Ivermectin 12mg Online Uk | Order Ivermectin 3mg” returned the following results.

    A Final LDT Rule in April!? Will FDA be Prepared?

    …how many comments were actually logged in; on December 7, FDA showed 19,655 comments, and the next day 6,732.) While some comments were boilerplate, others were comprehensive, detailed critiques of…

    Disclosures in a Small Space: The FTC’s Revisions to .Com Disclosures

    Somewhat later than anticipated, the Federal Trade Commission (“FTC”) has published a revised version of its guide, .Com Disclosures.  The FTC released the original guide 13 years ago, when mobile phones…

    Google to pay $500 Million Regarding Pharmacy Advertising; What is Next?

    …process, has “stringent standards” against the issuance of prescriptions based on online consultations, and does not certify Canadian online pharmacies. Google also hired a third-party company to detect pharmacy advertisers’…

    COPPA at 16

    …under 13; and Companies that have actual knowledge that they are collecting PI via another company’s website or online service that is directed to children. If a company is covered…

    Court Issues Ex Parte Temporary Restraining Order to Halt the Marketing of Acai Berry Weight-Loss Pills and Colon Cleansers

    By Carrie S. Martin – Yesterday, the Federal Trade Commission (“FTC”) held a press conference in Chicago to announce a lawsuit against several companies, including Central Coast Nutraceuticals, iLife, Simply…

    FTC Could Revise its Dot Com Disclosures Guidelines by Fall 2012

    …There were a few presentations that included research and data on how consumers read disclosures online, and the innovative techniques that some companies are creating to effectively communicate disclosures (including…

    The Clot Thickens! Bloggers Beware! Congress Requests Information from Drug Rep. Website on Anonymous Postings Concerning Early ENHANCE Study Results

    …other things, a group of letters sent by the U.S. House of Representatives Energy and Commerce Committee Oversight and Investigations Subcommittee and the U.S. Senate Finance Committee to myriad public…

    There’s a New Reporting Tool in Town

    …complainant who, for example, submitted an unreliable or inadequately documented complaint to the Agency, CDRH now has committed to “follow-up communication” and a tracking system. This will allow submitters to…

    “It’s In the Mail” Will Soon No Longer Apply to DEA Registration Applications

    …eliminating the “mail-in” option, believing that initial and renewal applications submitted online will be more effective for the agency and registrants. Requiring Online Submission of Applications for and Renewals of…

    Facebook “Pokes” Pharma Companies, Telehealth, and Online Pharmacies

    …of Facebook’s new policy requiring that pharmaceutical manufacturers, telehealth companies, and online pharmacies apply for permission to advertise on Facebook. This new policy goes into effect on August 25, 2021….

    FDA Sets Enforcement Date for Restaurant Menu (and Coupon!) Labeling

    …the customer can place an order” (emphasis added) includes an establishment’s homepage (e.g., www.CafeEtan.com), or only the specific webpage from which customers can place an order (e.g., www.CafeEtan.com/order). It is also…

    Further Musings about DEA’s “Suspicious Order” Proposed Rule: What Will a Registrant be Required to Report?

    …ordered The order form number for Schedule I and II controlled substances The unique transaction identification number for the suspicious order, and What information and circumstances render the order actually…

    DDMAC Digs Deep to Link Unbranded Websites to Violative Promotional Practices

    By Carrie S. Martin – FDA just released the Warning Letter it issued to Novartis Pharmaceuticals Corporation (“Novartis”) in April regarding two purportedly unbranded websites, www.gistalliance.com and www.cmlalliance.com (the “alliance…

    21st Century Cures Act: Three Notable Health Care Provisions and a Reminder to Sign Up for HP&M’s Two Complimentary Webinars

    …in the Act, please contact: Michelle L. Butler, mbutler@hpm.com, 202-737-7551 Alan M. Kirschenbaum, akirschenbaum@hpm.com, 202-737-4283 Jeffrey N. Wasserstein, jwasserstein@hpm.com, 202-737-9627 David C, Gibbons, dgibbons@hpm.com, 202-737-4286 Serra J. Schlanger, sschlanger@hpm.com, 202-737-4593…

    Highlights of Drug and Biologic Related Provisions of 21st Century Cures (Part Two)

    …or need more information, contact: Frank J. Sasinowski, fsasinowski@hpm.com, 202-737-4287 Josephine M. Torrente, jtorrente@hpm.com, 202-737-7554 David B. Clissold, dclissold@hpm.com, 202-737-7545 James E. Valentine, jvalentine@hpm.com, 202-724-1745 Michelle L. Butler, mbutler@hpm.com, 202-737-7551…

    Page 1 of 51123...1020...»Last »

    Search FDA Law Blog

    Subscribe

    Never miss a post from FDA Law Blog







    Latest Tweets

    Tweets by @fdalawblog

    Awards & Honors

    • Best Lawyers in AmericaÂź – 2025
    • Ranked in Chambers USA – 2024
  • Recent Posts
    • The OTC Fee Fallout: Are Hundreds of Companies Ignoring FDA’s User Fee Requirements? July 3, 2025
    • HP&M Seeks Experienced Regulatory Expert July 2, 2025
    • Controlled Substance Reporting Isn’t Just for DEA Anymore July 1, 2025
    • The RFD Process: Time for Reform? June 30, 2025
    • New Report on Patent Litigation Settlements Says that they are Critically Necessary to Ensure Prompt Generic and Biosimilar Market Entry June 26, 2025
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Copyright 2025 FDA Law Blog HPM
    • Disclaimer
    • Careers